Efficacy of low dose azithromycin versus rifampicin in recurrent furunculosis
DOI:
https://doi.org/10.66344/jpad.v31i2.1721Abstract
Objective To access the efficacy of low dose azithromycin versus rifampicin in recurrent furunculosis.
Methods This study was conducted at the Outpatient Department of Dermatology, DHQ teaching Hospital, Sargodha Medical College Sargodha from February 2019 to November 2019. 250 patients included in this study were divided into two groups containing 125 patients in each group. Both groups washed affected area or body with chlorhexidine soap daily, applied 2% mupirocin on lesions and in nostrils twice daily and took oral 400-600 mg tablet linezolid twice daily for 10-14 days. In addition, group A was prescribed azithromycin 500mg once weekly for next 3 months (12 weeks) and group B was prescribed rifampicin 450-600mg (10mg/kg body weight) once daily half hour before breakfast for 10 days. The drug is considered efficacious if the patient had no episode of furuncles during the 3‐month follow‐up after completion of full duration of treatment.
Results In group A, 17 patients (13.6%) reported back with recurrent furunculosis in contrast 16 patients (12.8%) of group B reported with recurrent furunculosis.
Conclusion It is concluded that of low dose azithromycin is as efficacious as rifampicin for treatment of recurrent furunculosis.
References
1. Ibler KS, Kromann CB. Recurrent furunculosis–challenges and management: a review. Clin Cosmet Investig Dermatol. 2014;7:59.
2. Jain AKC. Carbuncle is an Uncle of Furuncle‖-A case report. EAS J Med Surg. 2019;1(6):175-6.
3. Nowicka D, Grywalska E. Staphylococcus aureus and Host Immunity in Recurrent Furunculosis. Dermatology. 2019;235(4): 295-305.
4. Demos M, McLeod MP, Nouri K. Recurrent furunculosis: a review of the literature. Br J Dermatol. 2012;167(4):725–32.
5. El-Gilany A-H, Fathy H. Risk factors of recurrent furunculosis. Dermatol Online J. 2009;15(1):16.
6. Davido B, Dinh A, Salomon J, Roux AL, Gosset-Woimant M, Pierre I, et al. Recurrent furunculosis: Efficacy of the CMC regimen-skin disinfection (chlorhexidine), local nasal antibiotic (mupirocin), and systemic antibiotic (clindamycin). Scand J Infect Dis. 2013; 45(11):837–41.
7. Smith K, Perez A, Ramage G, Gemmell CG, Lang S. Comparison of biofilm-associated cell survival following in vitro exposure of meticillin-resistant Staphylococcus aureus biofilms to the antibiotics clindamycin, daptomycin, linezolid, tigecycline and vancomycin. Int J Antimicrob Agents. 2009; 33(4):374-8.
8. Naqvi F, Inayat S, Mubeen A, Muhammad F, Faraz AAK, Qamar MM. Efficacy of low dose azithromycin in recurrent furunculosis. J Pakistan Assoc Dermatol. 2020; 30(4):667-72.
9. Mashhood AA, Shaikh ZI, Qureshi SM, Malik SM. Efficacy of rifampicin in eradication of carrier state of Staphylococcus aureus in anterior nares with recurrent furunculosis. J Coll Physicians Surg JCPSP. 2006;16(6):396-9.
10. Renteria AE, Maniakas A, Mfuna LE, Asmar M, Gonzalez E, Desrosiers M. Low‐dose and long‐term azithromycin significantly decreases Staphylococcus aureus in the microbiome of refractory CRS patients. In: International Forum of Allergy & Rhinology. Wiley Online Library; 2020.
11. Farr B, Mandell GL. Rifampin. Med Clin North Am. 1982;66(1):157-68.
12. Hoss DM, Feder HM. Addition of rifampin to conventional therapy for recurrent furunculosis. Arch Dermatol. 1995; 131(6):647-8.
13. Aminzadeh A, Demircay Z, Ocak K, Soyletir G. Prevention of chronic furunculosis with low‐dose azithromycin. J Dermatolog Treat. 2007;18(2):105-8.
14. Shallcross LJ, Hayward AC, Johnson AM, Petersen I. Incidence and recurrence of boils and abscesses within the first year: a cohort study in UK primary care. Br J Gen Pract. 2015;65(639):e668–76.
Downloads
Published
Issue
Section
License
Copyright (c) 2021 Farwa Naqvi, Zaib, Shahbaz Ali, Aisha Ghias, Fauzia Perveen, Ahmad Amin Khan Fraz
This work is licensed under a Creative Commons Attribution 4.0 International License.
Submission declaration
Authors retain the copyright to their work and grant the 'Journal of Pakistan Association of Dermatologists (JPAD)' the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.
By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.
